Humoral and cellular immunogenecity of DNA vaccine based on hepatitis B core gene in rhesus monkeys

Table 1 Anti-HBc in sera of experimental and control monkeys

Monkey No.	Group	Anti-HBc antibody					End-point
		0 month	2 month	4 month	6 month	8 month
1	Experimental	Na	Pb	N/Dc	N/D	N/D	1:36450
2	Experimental	N	N	P	P	P	1:109350
3	Control	N	N	N	N	N	1:150
4	Control	N	N	N	N	N	1:150

^aN: Negative

^bP: Positive (in Abbott Imx System, the detected value less than 1.00 was considered positive for anti-HBc).

^cnot detected because of death.

Table 2 Subclasses of anti-HBc IgG and IgG1/IgG2 ratio in rhesus monkeys’ sera

Monkey No.	IgG1	IgG2	IgG3	IgG4	IgG1/IgG2
1	0.61 + 0.01a	1.02 + 0.08	0.32 + 0.02	0.12 + 0.01	0.60
2	0.61 + 0.04	1.05 + 0.04	0.40 + 0.01	0.18 + 0.03	0.58

^aThe values indicated x^-± s of triplicate wells.

Table 3 IFN-γ and IL-4 values in culture supernatant of PBMCs

Monkey No.	Group	IFN-γ (ng/L)	IL-4 (ng/L)
2	Experimental	15.63	6.25
3	Control	< 3.13	6.25

Table 4 HBcAg specific PBMC proliferation activity*

Monkey No.	Group	HBcAg dose for stimulation (μg/well)
		0	5	10	12.5
2	Experimental	354.4 ± 64.5	984.9 ± 105.4a (2.74)	1364.9 ± 47.9a (3.83)	890 ± 155.6a (2.12)
3	Control	198.4 ± 3.9	274.5 ± 33.2 (1.37)	261.5 ± 28.2 (1.32)	250 ± 70.0 (1.24)

*The values in the table refer to CPM (x^-± s from each triplicate well), the values in the brackets indicate stimulation index (SI).

^aP < 0.05 vs control monkey.